Efferon, a biotech startup featured in TechCrunch Disrupt 2026, has developed a medical device called Efferon NEO that filters deadly cytokines and toxins from children's blood to treat pediatric sepsis. Unlike existing devices that target only one type of toxin, Efferon's absorber can remove both endotoxins and cytokines simultaneously, addressing a critical gap in treating sepsis in young patients.
Background
Pediatric sepsis is a leading cause of childhood mortality worldwide, claiming approximately 3 million lives annually among children under five. Current extracorporeal blood filtration devices for sepsis treatment are primarily designed for adults and lack pediatric-specific formulations.
- Source
- TechCrunch
- Published
- Oct 11, 2026 at 11:00 PM
- Score
- 6.0 / 10